Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office
Retrieved on:
Thursday, December 29, 2022
Dementia, Protein, PMID, Iron, United States Patent and Trademark Office, DOI, Central nervous system, Pathology, Lisa Ng, Thought, Atrophy, Infection, SAN, Dopamine, Brain, Drug discovery, Social skills, Tremor, Parkinson's disease, Disease, Patent, Alzheimer's disease, Heredity, Biomarker, ISSN, ATH, Malnutrition, Rigidity, Shamsi Fazlollahi, Neurodegeneration, Multimedia, Fatigue, Constipation, ASX, Ageing, Therapy, Dehydration, S, Genetics, Pharmaceutical industry, Medical imaging, Vaccine, PD, Neuroscience, Parkinsonism, Alterity
MELBOURNE, Australia and SAN FRANCISCO, Dec. 29, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a new composition of matter patent has been allowed by the United States Patent and Trademark Office (USPTO). The patent was allowed following expedited review by the USPTO.
Key Points:
- Importantly, the patent covers iron chaperones which are small molecules capable of binding and redistributing excess iron in the central nervous system.
- "This patent strengthens our portfolio of compounds for treating important neurodegenerative diseases such as Parkinson's and Alzheimer's," said David Stamler, M.D., Chief Executive Officer, Alterity.
- "With this patent, our discovery team has created a new scaffold that extends our approach of targeting key proteins implicated in these diseases.
- Progress in Neurobiology, Volume 155, 2017, Pages 96-119, ISSN 0301-0082, https://doi.org/10.1016/j.pneurobio.2015.09.012
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.